{"product_id":"obetan-obeticholic-acid-ef-bc-8coca-5mg","title":"Obetan  (Obeticholic acid)","description":"\u003cdiv class=\"woocommerce-product-details__short-description\"\u003e\r\n\r\n\u003cstrong\u003eIndications\u003c\/strong\u003e\r\n\r\nOrbetan is a farnesol X receptor (FXR) agonist. Orbetan combined with ursodeoxycholic acid\r\n\r\n(Ursodeoxycholicacid, UDCA) Used for primary biliary bile ducts with insufficient response to UDCA\r\n\r\nInflammatory (previously known as primary biliary cirrhosis, PBC) in adult patients, or as a monotherapy for\r\n\r\nAdult patients with primary biliary cholangitis intolerant to UDCA.\r\n\r\n\u003cstrong\u003eDose and administration method\u003c\/strong\u003e\r\n\u003col\u003e\r\n \t\u003cli\u003eMethod of administration\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eRecommended dose (TDC): 24 mg orally, once a day.\u003c\/li\u003e\r\n \t\u003cli\u003eRecommended dose (RCC): 5mg everolimus + 18mg Levinib, orally, once a day. Follow Follow medication guidelines.\u003c\/li\u003e\r\n \t\u003cli\u003eFor patients with DTC and RCC, the dose can be adjusted.\u003c\/li\u003e\r\n \t\u003cli\u003eIn patients with severe renal or hepatic impairment, the dose of DTC is 14 mg once a day, and the dose of RCC is The dose is 10 mg once a day.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003col start=\"2\"\u003e\r\n \t\u003cli\u003eDosage specifications\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eCapsules, 5mg.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003col start=\"3\"\u003e\r\n \t\u003cli\u003eContraindications: None.\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003cstrong\u003eWarnings and Precautions\u003c\/strong\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eHypertension: Before treatment with Levigne, blood pressure needs to be controlled. Even if the patient has the best resistance to high Blood pressure therapy, but Levigny is not recommended for patients with grade 3 hypertension. For patients with life-threatening hypertension In those cases, stop the medication.\u003c\/li\u003e\r\n \t\u003cli\u003eHeart failure: Closely monitor the clinical symptoms and signs of cardiac decompensation during medication. For 3 Lavigne is not recommended for patients with grade new dysfunction. For patients with grade 4 cardiac insufficiency, stop medication.\u003c\/li\u003e\r\n \t\u003cli\u003eArterial thromboembolic events: After an arterial thromboembolic event, Levigny should be terminated.\u003c\/li\u003e\r\n \t\u003cli\u003eHepatotoxicity: Before the start of Levigne treatment and throughout the treatment, regularly monitor liver function. For level 3 and\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n(Please read this notice carefully and take the medicine according to this notice or under the guidance of a doctor)\r\n\u003cul\u003e\r\n \t\u003cli\u003eLavigne is not recommended for patients with liver impairment above. For patients with liver failure, stop medication.\u003c\/li\u003e\r\n \t\u003cli\u003eProteinuria: Before the start of Levigne treatment and throughout the treatment, regularly monitor proteinuria. For 24 hours\u003c\/li\u003e\r\n \t\u003cli\u003eLavigne is not recommended for patients with urinary protein ≥ 2 g. For patients with nephrotic syndrome, stop medication.\u003c\/li\u003e\r\n \t\u003cli\u003eDiarrhea: can cause severe or recurring diarrhea. Use standard anti-diarrheal treatment. For level 3 and above\u003c\/li\u003e\r\n \t\u003cli\u003eLavigne is not recommended for patients with diarrhea.\u003c\/li\u003e\r\n \t\u003cli\u003eRenal failure and renal impairment: Lavigne is not recommended for patients with grade 3 or 4 renal failure\/impairment.\u003c\/li\u003e\r\n \t\u003cli\u003eGastrointestinal perforation and fistula formation: in patients with gastrointestinal perforation or life-threatening fistula, stop Levigny.\u003c\/li\u003e\r\n \t\u003cli\u003eProlonged QT interval: All patients should monitor and correct electrolyte abnormalities. For occurrence of grade 3 or greater Lavigne is not recommended for patients with prolonged QT events.\u003c\/li\u003e\r\n \t\u003cli\u003eHypocalcemia: Monitor blood calcium levels at least once a month, and supplement calcium when needed. Reversible posterior leukoencephalopathy syndrome (RPLS): During RPLS, Lavigne is not recommended until RPLS complete relief.\u003c\/li\u003e\r\n \t\u003cli\u003eBleeding events: Levigny is not recommended for grade 3 bleeding events. For grade 4 bleeding events, stop medication.\u003c\/li\u003e\r\n \t\u003cli\u003eThyroid stimulating hormone (TSH) inhibition\/abnormal thyroid function: monitor TSH levels monthly, And use thyroid replacement medicine as needed.\u003c\/li\u003e\r\n \t\u003cli\u003eEmbryo-fetal toxicity: may cause harm to the fetus. Advise the fetus of potential risks and use effective contraception.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cstrong\u003eAdverse reactions\u003c\/strong\u003e\r\n\r\nIn DTC, the most common adverse reactions of Levigne (incidence greater than or equal to 30%) are hypertension,\r\n\r\nFatigue, diarrhea, joint pain\/myalgia, loss of appetite, weight loss, nausea, stomatitis, headache, vomiting,\r\n\r\nProteinuria, palmar-foot-plantar erythema syndrome, abdominal pain, and dysphonia.\r\n\r\nIn RCC, the most common adverse reactions (greater than 30%) of Levinib+everolimus are diarrhea, fatigue,\r\n\r\nJoint pain\/myalgia, loss of appetite, vomiting, nausea, stomatitis\/oral inflammation, high blood pressure, peripheral edema,\r\n\r\nCough, abdominal pain, difficulty breathing, skin rash, weight loss, bleeding episodes, and proteinuria.\r\n\r\n\u003cstrong\u003eStorage method\u003c\/strong\u003e\r\n\r\nStore at room temperature of 25°C (77°F), and allow to take out to 15-30°C (59-86°F).\r\n\r\n\u003c\/div\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797946724395,"sku":"RL142023090183","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/1663309480-f5452a9117c7a98.png?v=1787022079","url":"https:\/\/xomeds.com\/products\/obetan-obeticholic-acid-ef-bc-8coca-5mg","provider":"XOMEDS","version":"1.0","type":"link"}